To evaluate the research progress and clinical applications of immune checkpoint inhibitors (ICIs) in lung cancer treatment, highlighting specific challenges such as resistance mechanisms and future directions for personalized therapy.
Key Findings:
ICIs have significantly improved survival rates in lung cancer patients, especially in advanced stages, but long-term efficacy is limited by primary and acquired resistance.
Primary and acquired resistance to ICIs is a major challenge, influenced by tumor microenvironment and immune evasion mechanisms, necessitating further research into overcoming these barriers.
Existing biomarkers for predicting ICI response, such as PD-L1 expression and tumor mutational burden, have limitations in standardization and variability, impacting their clinical utility.
Interpretation:
The integration of ICIs into lung cancer treatment represents a major advancement, but the variability in patient response and the presence of resistance mechanisms necessitate a personalized approach to therapy, focusing on individual patient characteristics and tumor profiles.
Limitations:
Insufficient standardization of biomarkers for predicting treatment efficacy, leading to inconsistent clinical outcomes.
Variability in patient responses due to tumor heterogeneity and immune microenvironment factors, complicating treatment decisions.
Challenges in managing immune-related adverse events (irAEs), such as pneumonitis and colitis, that may require treatment modification and close monitoring.
Conclusion:
Future advancements in ICI therapy should focus on enhancing precision and safety, aiming for more tailored clinical interventions to improve outcomes in lung cancer patients, particularly through the development of novel biomarkers and combination therapies.
